

International Tumor Profiling Requisition

Complete and email requisition with copy of pathology report and clinical history to service@precisiononcology.com.au. Please send the original copy of the requisition with the specimen.



TREATING PHYSICIAN INFORMATION			PATIENT INFORMATION		
Office/Facility Name	Precision Oncology Group Pty Ltd		Last Name	First Name	Initial
Ordering Physician	Physician Email Address		Date of Birth (dd/mm/yyyy)	Gender <input type="checkbox"/> Male <input type="checkbox"/> Female	
Address			Address		
City	Country	Postal Code	City	Country	Postal Code
Phone	Fax		Phone	Email Address	

PATHOLOGY INFORMATION <i>(Include a copy of the pathology report)</i>				
Institution/Hospital Name			Pathologist Name	
Institution/Hospital Address:		City	Country	Postal Code
Phone	Fax		Return Specimen Block To: <input type="checkbox"/> Pathology <input type="checkbox"/> Ordering Physician <input type="checkbox"/> Caris to Archive <i>Return addresses must be provided above in order to return block</i>	

BILLING INFORMATION
<input type="checkbox"/> Self-pay: Payment is required before testing can begin. A customer services representative will contact the patient directly for payment information. <input type="checkbox"/> Other, please specify: _____

CLINICAL/SPECIMEN INFORMATION <i>(Include a copy of the pathology report)</i>		
Primary Tumor Site	Shipment Tracking #	
Specimen Site	Specimen/Block ID#(s)	Date & Time of Collection
Tissue Type(s): <input type="checkbox"/> FFPE Block <input type="checkbox"/> Unstained Slides	Duration of Fixation (FFPE Blocks)	

CARIS MOLECULAR INTELLIGENCE® TUMOR PROFILING OPTIONS
The biomarkers included in MI Profile may change from time-to-time. Before ordering, please refer to the Website, www.Carismolecularintelligence.com/profilemenu , to view the most up-to-date listing of biomarkers that will be performed by tumor type.
SERVICE Solid tumor biomarker analysis for therapeutic decision support and clinical trials matching <i>(for details, visit www.Carismolecularintelligence.com/profilemenu)</i> <input type="checkbox"/> MI Profile™ Multiple platform biomarker analysis (Mutation Analysis by NGS; Fusion Analysis by NGS; Pyro Sequencing; Fragment Analysis; IHC; ISH) The definitive list of biomarkers analyzed by tumor type are available online at www.Carismolecularintelligence.com/profilemenu.

PLEASE SHARE A COPY OF THE FINAL REPORT WITH:
<input type="checkbox"/> Pathology <input type="checkbox"/> Other Physician <i>(please specify):</i> _____ Email: _____

<small>Notice: This requisition constitutes an order for services. I certify (a) that the services are medically indicated and necessary and will assist me in treating my patient, (b) that I maintain and will make available patient medical records documenting the foregoing, and (c) I have supplied information to the patient regarding testing and if required by law, the patient has given consent for testing to be performed.</small>	Physician or Practitioner Signature	Print Name	Date
---	-------------------------------------	------------	------

FINAL REPORT WILL BE DELIVERED IN ENGLISH. PLEASE SEE THE REVERSE FOR PATIENT CONSENT REQUIREMENTS AND OPTIMAL SPECIMEN REQUIREMENTS. Terms and conditions apply. Visit <http://www.CarisLifeSciences.com/order-now/client-services/> to view the terms and conditions in full.



Acknowledgment of Consent

By submitting this requisition, you, as the patient's physician, represent and verify that the patient has provided clear, unambiguous and explicit consent to send the patient's specimen and sensitive medical and other personal information to Caris Life Sciences, and to transfer that information to the United States for processing. Additionally, you represent that, as applicable to provisioning of this service, you and your office have complied with all applicable national and local privacy requirements and regulations.

Office Checklist for Caris Molecular Intelligence

- Requisition (Completed, Signed and Dated)
- Pathology Report
- Sufficient Tumor Specimen (Detailed Below)
- Clinical History

Formalin Fixed Paraffin Embedded (FFPE) Samples

Sufficient tumor must be present to complete all analysis. If you have any questions, please contact the Caris Care Team at 1300 308 213.

SPECIMEN TYPE	SPECIMEN REQUIREMENTS
Fixed Tissue	One (1) tumor-containing formalin fixed paraffin embedded block (FFPE) from most recent surgery or biopsy. Successive four (4) micron sections will be created from the block until sufficient material for the testing orders is obtained. For the molecular analysis, tumor cells will be excised by microdissection until a total area of at least 50mm ² is obtained.
Unstained Slides	Unstained, positively charged, unbaked slides from one single, tumor-containing formalin fixed paraffin embedded block; 4 micron sections <ul style="list-style-type: none"> • MI Profile™ - 44 slides Note: At least a 5mm x 5mm section of tissue per slide is required. For small biopsies (tissue area < 5 mm x 5 mm) please cut two sections per slide for at least one half of the slides to ensure sufficient material for molecular assays.
Core Needle Biopsy	Four to six (4-6) biopsies formalin fixed paraffin embedded <ul style="list-style-type: none"> • 18 gauge needle preferred
Fine Needle Aspirate (FNA)	One (1) formalin fixed paraffin embedded block containing sufficient tumor
Malignant Fluid Cell Block	One (1) formalin fixed paraffin embedded cell block containing sufficient tumor (20% or more tumor nuclei).

Insufficient Specimen Quantity – Prioritisation of Tests

In the event that a specimen is received with an insufficient quantity of tissue or insufficient percent tumor required to perform the entire profile or individual tests indicated on the requisition, Caris Life Sciences® will fax the ordering physician the proposed list of tests. The physician may amend this list to include any tests that are offered within the test menu. The ordering physician should review the proposed list of tests within 48 hours in order to provide timely results. Please note: *turnaround time may be longer for specimens with limited tissue.*

The results for biomarkers tested under this requisition will be provided in a report associating one or more treatment agents to biomarkers based on published medical evidence, which may include published studies performed in the tumor type present in the tested sample or derived from a different tumor type. Decisions regarding care and treatment should not be based solely on selection of a test such as this test or the information provided related to this requisition. Decisions on patient care and treatment must be based on the treating physician's independent medical judgment, taking into consideration all relevant patient information, such as family history, physical examinations, results of other diagnostic tests, and patient preferences, and in accordance with the applicable standard of care. The selection of any or none of the matched agents is ultimately and solely in the discretion of the treating physician. Physician or practitioner hereby acknowledges and agrees to comply with any local, state/provincial, or national laws or regulations, rules or order of any governmental body, having jurisdiction over activities considered under this requisition.